10 Year Financial Data of United Therapeutics Corporation (UTHR)

66.35 (1y: +51%)

Market Cap	3.38 B	P/E(ttm)	11.70
Enterprise Value	2.97 B	P/B	3.10

UTHR- NAS (USA)
United Therapeutics Corporation

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$66.35

2 Medium Warning Signs 1 Good Sign

Bookmark

Annual Rates (per share)	10 yrs*	5 yrs*	12 months*
Revenue Growth (%)	33.6	31	33.9
EBITDA Growth (%)	0	0	18.8
Free Cash Flow Growth (%)	0	0	110.8
Book Value Growth (%)	22	16.6	17.9

*12-month growth rate is calculated with the per share revenue (EBITDA, FCF, earnings) of the last 12 months over the per share revenue (EBITDA, FCF, earnings) over the previous 12 months. 5-year and 10-year growth rates are calculated with least-square regression based on the 5-year and 10-year numbers.

Trendline:

Export:

Print This Table Print

See this page for the explanation of the data and charts * All numbers are in millions except for per share data

Per Share Data	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue per Share ($)	1.26	1.58	2.30	3.31	4.70	6.15	6.59	10.15	12.51	17.19	18.11	3.71	4.18	4.52	4.73	4.68
EBITDA per Share	-0.22	0.33	0.90	0.63	0.16	-1.69	0.67	3.06	5.70	8.42	8.29	2.06	2.07	1.64	2.63	1.95
Free Cashflow per Share	-0.37	0.33	0.75	0.75	0.23	-3.79	0.04	3.24	3.61	3.97	5.84	-0.05	0.81	1.62	1.63	1.78
Earnings per Share ($)	-0.24	0.33	1.29	1.53	0.44	-0.94	0.35	1.78	3.67	5.71	5.60	1.29	1.34	1.46	1.61	1.19
Book Value per Share	3.97	4.10	5.46	4.24	6.59	11.08	11.63	14.85	15.97	20.34	21.97	18.63	18.72	19.80	21.02	21.97
Month End Stock Price	11.48	22.58	34.56	27.19	48.83	31.28	52.65	63.22	47.25	53.42	60.87	47.13	49.38	55.88	53.42	60.87
Ratios	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Return on Equity %	-5.90	8.10	23.60	36.10	6.70	-8.40	3.00	12.00	23.00	28.10	21.60	27.60	28.80	29.60	30.80	21.60
Return on Assets %	-5.60	7.50	22.30	15.50	3.40	-4.90	1.90	7.40	14.40	18.70	14.80	18.00	18.40	18.80	20.40	14.80
Return on Capital - Joel Greenblatt %	-43.40	41.70	88.30	44.50	5.80	-36.50	9.00	65.40	102	90.40	84.40	109	99.20	75.60	110	84.40
Debt to Equity	0.01	--	--	1.22	0.85	0.55	0.38	0.35	0.21	0.25	0.24	0.26	0.27	0.26	0.25	0.24

Gross Margin %	87.30	88.80	89.40	89.30	89.40	89.30	87.70	87.80	88.00	87.00	88.00	88.20	86.90	88.50	84.60	88.00
Operating Margin %	-21.60	17.90	37.00	18.20	3.00	-29.10	7.00	27.20	42.80	46.00	38.40	52.30	46.80	33.30	52.70	38.40
Net Margin %	-18.70	21.00	56.10	46.30	9.40	-15.20	5.30	17.50	29.30	33.20	25.40	34.60	32.10	32.20	34.10	25.40

Days Sales Outstanding	72.60	73.20	59.20	58.50	51.30	39.70	52.60	44.60	43.60	46.50	37.60	39.70	39.80	40.90	43.50	37.60
Days Inventory	437	355	334	258	217	175	212	177	189	114	123	173	143	152	90.00	123
Inventory Turnover	0.80	1.00	1.10	1.40	1.70	2.10	1.70	2.10	1.90	3.20	0.70	0.50	0.60	0.60	1.00	0.70

Debt to Revenue	0.02	--	--	1.57	1.19	0.99	0.68	0.51	0.26	0.30	1.13	1.31	1.20	1.13	1.13	1.13
COGS to Revenue	0.13	0.11	0.11	0.11	0.11	0.11	0.12	0.12	0.12	0.13	0.12	0.12	0.13	0.12	0.15	0.12
Inventory to Revenue	0.15	0.11	0.10	0.08	0.06	0.05	0.07	0.06	0.06	0.04	0.16	0.22	0.21	0.19	0.15	0.16
Interest Exp. to Revenue %	4.36	4.05	4.60	6.40	5.42	3.91	-2.09	-2.78	-2.41	-1.39	-1.41	-1.40	-1.25	-1.34	-1.55	-1.41

Asset Turnover	0.30	0.36	0.40	0.33	0.36	0.32	0.35	0.42	0.49	0.56	0.14	0.13	0.15	0.15	0.15	0.14
Buyback Ratio	41.00	-45.90	-23.00	-19.50	-294	351	--	--	--	--	-2.20	--	--	--	--	-2.20
Income Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue	53.34	73.59	116	160	211	281	370	604	743	916	957	204	226	242	244	245
Cost of Goods Sold	6.78	8.25	12.32	17.03	22.26	30.07	45.32	73.47	88.90	119	125	24.03	29.63	27.97	37.67	29.31
Gross Profit	46.56	65.34	104	143	189	251	325	530	654	797	832	180	196	215	206	216

Selling, General, &Admin. Expense	22.67	21.53	24.66	54.03	99.03	94.31	176	200	156	202	233	39.79	53.26	68.63	40.07	71.36
Research &Development	35.42	30.60	36.05	57.57	83.35	239	122	167	180	173	190	33.66	37.10	65.16	37.48	50.43
Earnings Before DDA	-9.20	15.49	45.31	30.45	7.26	-77.52	37.40	182	338	449	438	113	112	87.63	136	102

Depreciation, Depletion and Amortization	2.33	2.28	2.41	1.46	0.96	4.54	11.39	17.92	20.54	27.15	28.66	6.65	6.29	6.92	7.29	8.17

Operating Income	-11.53	13.21	42.89	28.98	6.30	-82.06	26.00	164	318	422	409	107	106	80.72	129	94.04
Interest Income/Expense	2.32	2.98	5.33	10.22	11.43	11.01	-7.73	-16.78	-17.92	-12.70	-13.30	-2.85	-2.82	-3.25	-3.77	-3.46
Net Income	-9.97	15.45	65.02	73.97	19.86	-42.79	19.46	106	218	304	296	70.76	72.32	78.11	83.26	62.33

Earnings per Share ($)	-0.24	0.33	1.29	1.53	0.44	-0.94	0.35	1.78	3.67	5.71	5.60	1.29	1.34	1.46	1.61	1.19
Total Shares Outstanding	42.27	46.70	50.41	48.28	44.90	45.80	56.13	59.52	59.40	53.28	52.38	55.01	53.94	53.59	51.57	52.38
Balance Sheet	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Cash and cash equivalents	68.56	82.79	125	228	290	236	229	627	403	479	671	409	392	503	479	671
Accounts Receivable	10.61	14.77	18.81	25.58	29.66	30.60	53.26	73.71	88.68	117	101	89.15	98.58	109	117	101
Inventory	8.12	8.01	11.26	12.05	13.21	14.37	26.36	35.52	45.98	37.25	39.74	45.76	46.63	46.85	37.25	39.74
Other Current Assets	2.43	4.93	11.20	12.00	19.54	16.43	15.39	28.18	24.32	35.39	32.83	30.04	33.02	58.93	35.39	32.83
Total Current Assets	89.72	110	167	277	352	297	325	764	562	668	845	574	571	718	668	845

Property, Plant and Equipment	15.23	17.80	21.80	34.68	69.35	221	304	306	366	454	449	402	436	440	454	449
Intangible Assets	13.91	13.43	12.95	10.61	8.43	7.84	18.42	9.86	22.09	16.41	15.66	24.92	17.06	16.66	16.41	15.66
Other Long Term Assets	60.65	65.44	89.90	156	157	345	405	351	567	488	388	561	533	473	488	388
Total Assets	180	207	291	479	587	871	1,052	1,432	1,518	1,627	1,697	1,561	1,556	1,647	1,627	1,697

Accounts Payable	9.79	13.82	14.37	18.36	19.94	41.19	48.51	66.43	104	83.19	77.53	66.93	75.91	97.77	83.19	77.53
Current Portion of Long-Term Debt	0.77	0.02	0.02	0.01	250	--	220	236	--	--	--	--	--	--	--	--
Other Current Liabilities	0.06	0.03	0.13	0.88	2.81	16.64	61.40	126	108	93.57	99.07	109	112	130	93.57	99.07
Total Current Liabilities	10.62	13.86	14.52	19.25	273	57.83	330	429	213	177	177	176	188	228	177	177

Long-Term Debt	0.03	0.01	0.01	250	0.00	279	30.33	68.93	194	275	278	268	271	273	275	278
Other Long-Term Liabilities	1.09	1.65	1.78	4.68	18.47	26.56	38.02	50.13	163	90.85	92.35	93.08	88.38	85.68	90.85	92.35
Total Liabilities	11.74	15.52	16.31	274	291	364	399	548	570	543	547	537	547	587	543	547

Common Stock	0.22	0.23	0.24	0.25	0.27	0.28	--	0.60	0.62	0.62	0.62	0.62	0.62	0.62	0.62	0.62
Retained Earnings	-195	-180	-115	-41.36	-21.50	-78.51	-74.75	31.17	249	553	616	320	392	470	553	616
Additional Paid-In Capital	369	376	393	409	548	659	799	929	993	1,016	1,028	997	999	1,013	1,016	1,028
Treasury Stock	-6.87	-6.87	-6.87	-165	-232	-67.40	-67.40	-67.40	-283	-471	-477	-283	-371	-414	-471	-477
Total Equity	168	192	275	205	296	508	653	884	948	1,084	1,151	1,025	1,010	1,061	1,084	1,151
Cashflow Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Net Income	-9.97	15.45	65.02	73.97	19.86	-42.79	19.46	106	218	304	296	70.76	72.32	78.11	83.26	62.33
Depreciation, Depletion and Amortization	2.33	2.28	2.41	1.46	0.96	4.54	11.39	17.92	20.54	27.15	28.66	6.65	6.29	6.92	7.29	8.17
Cash Flow from Others	-0.92	3.05	-23.73	-23.65	28.27	-10.92	66.77	87.70	11.79	-7.96	59.07	-39.82	8.78	8.42	14.66	27.21
Cash Flow from Operations	-8.56	20.78	43.70	51.78	49.08	-49.17	97.62	212	250	324	384	37.59	87.39	93.45	105	97.70

Investment for Property, Plant & Equipement	-7.00	-5.22	-6.12	-15.63	-38.66	-124	-95.40	-18.64	-35.98	-112	-75.87	-40.28	-43.64	-6.73	-21.26	-4.24
Cash Flow from Acquisitions	--	--	--	--	--	--	1.21	--	-3.55	--	--	--	--	--	--	--
Cash Flow from Investing	-47.54	-12.87	-71.28	-104	-21.71	-172	-161	-209	-121	-163	-107	-45.99	-0.29	47.61	-165	10.64

Net Issuance of Stock	4.09	7.09	14.97	-179	-8.72	150	--	--	--	-188	-193	--	-88.00	-42.93	-57.08	-4.53
Net Issuance of Debt	-2.08	-0.77	-0.80	242	-0.01	-0.02	--	38.56	-1.04	-1.00	-1.00	--	--	--	-1.00	--
Cash Flow for Dividends	--	--	--	--	29.60	--	--	--	--	--	--	--	--	--	--	--
Other Financing	--	--	--	10.76	0.00	63.03	36.48	108	-217	19.86	22.95	2.13	1.67	7.97	8.09	5.22
Cash Flow from Financing	2.01	6.32	14.17	74.13	20.88	213	36.48	147	-218	-169	-171	2.13	-86.33	-34.95	-49.99	0.69

Net Change in Cash	-54.09	14.22	-13.41	21.89	48.26	-9.87	-29.10	152	-89.49	-8.65	105	-6.01	0.35	106	-109	108

Free Cash Flow	-15.57	15.56	37.58	36.15	10.43	-174	2.22	193	214	212	308	-2.70	43.75	86.72	83.95	93.46
Valuation Ratios (Daily)	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

PE Ratio(ttm)
Price to Tangible Book
Price-to-Free-Cash-Flow ratio
PS Ratio
EV-to-Revenue
EV-to-EBITDA
EV-to-EBIT
Earnings Yield (Joel Greenblatt)
Forward Rate of Return
Shiller PE Ratio
Valuation and Quality	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Market Cap
Enterprise Value
Month End Stock Price
Net Cash (per share)
Net Current Asset Value (per share)
DCF (per share)
Median PS (per share)
Peter Lynch Fair Value (per share)
Graham Number (per share)
Altman Z-Score
Piotroski F-Score
Beneish M-Score

Switch to Another Stock:

UTHR Quarterly/Annuals Reports

UTHR: 10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer): (10-Q) - 2012-11-01
UTHR: 10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer): (10-Q) - 2012-07-26
UTHR: 10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer): (10-Q) - 2011-10-27
UTHR: 10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer): (10-Q) - 2011-07-28
UTHR: 10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer): (10-Q) - 2011-04-28

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles

UTHR Quarterly/Annuals Reports